| human | Q5 |
| P6178 | Dimensions author ID | 013023123727.43 |
| P2671 | Google Knowledge Graph ID | /g/122pkw7d |
| P1960 | Google Scholar author ID | kEA6Ia0AAAAJ |
| P496 | ORCID iD | 0000-0001-6637-1072 |
| P1153 | Scopus author ID | 9233235300 |
| P4012 | Semantic Scholar author ID | 1382494699 |
| P27 | country of citizenship | Spain | Q29 |
| P69 | educated at | University of Salamanca | Q308963 |
| P108 | employer | University of Salamanca | Q308963 |
| P734 | family name | González | Q5576697 |
| González | Q5576697 | ||
| González | Q5576697 | ||
| P735 | given name | Marcos | Q6757805 |
| Marcos | Q6757805 | ||
| P1412 | languages spoken, written or signed | Spanish | Q1321 |
| P106 | occupation | physician | Q39631 |
| researcher | Q1650915 | ||
| P551 | residence | Spain | Q29 |
| P21 | sex or gender | male | Q6581097 |
| Q50784932 | A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. |
| Q90668344 | A New Next-Generation Sequencing Strategy for the Simultaneous Analysis of Mutations and Chromosomal Rearrangements at DNA Level in Acute Myeloid Leukemia Patients |
| Q37112857 | A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. |
| Q71677050 | A new method for the analysis of plasma cell DNA content in multiple myeloma samples using a CD38/propidium iodide double staining technique |
| Q58041421 | Actualización de las guías nacionales de consenso del Grupo Español de Leucemia Linfocítica Crónica para el tratamiento y seguimiento de la leucemia linfocítica crónica |
| Q69876605 | Acute leukemia of hybrid phenotype: T lymphoid and myelomonocytic markers |
| Q73583883 | Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13 and CD38 expresssion |
| Q73138436 | Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin's lymphomas |
| Q51035561 | Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. |
| Q50572223 | Application of a molecular diagnostic algorithm for haemophilia A and B using next-generation sequencing of entire F8, F9 and VWF genes. |
| Q45973697 | Array comparative genomic hybridization identifies genetic regions associated with outcome in aggressive diffuse large B-cell lymphomas. |
| Q69584252 | B-cell chronic lymphocytic leukaemia: prognostic value of the immunophenotype and the clinico-haematological features |
| Q48396875 | BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). |
| Q37469213 | Bisphosphonate-related osteonecrosis: genetic and acquired risk factors. |
| Q71093825 | Bone marrow necrosis associated with tumor emboli and disseminated intravascular coagulation |
| Q104758416 | Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative |
| Q42573854 | CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia. |
| Q56901242 | CTLA-4 polymorphisms and clinical outcome after allogeneic stem cell transplantation from HLA-identical sibling donors |
| Q38955569 | CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival. |
| Q55282193 | CXCR7 expression in diffuse large B-cell lymphoma identifies a subgroup of CXCR4+ patients with good prognosis. |
| Q40600684 | Cerebral toxoplasmosis and Guillain-Barré syndrome after allogeneic peripheral stem cell transplantation. |
| Q72680405 | Cerebrospinal fluid levels beta 2 microglobulin and ferritin in lymphoproliferative disorders |
| Q40137810 | Characterization of a reference material for BCR-ABL (M-BCR) mRNA quantitation by real-time amplification assays: towards new standards for gene expression measurements. |
| Q72233543 | Characterization of aberrant phenotypes in acute myeloblastic leukemia |
| Q44360456 | Chimerism analysis following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning. |
| Q58001012 | Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis |
| Q59413209 | Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results |
| Q68090577 | Clinical and immunological findings in large B-cell chronic lymphocytic leukemia |
| Q82286372 | Clinical and prognostic value of discrepancies in microsatellite DNA regions between recipient and donor in human leukocyte antigen-identical allogeneic transplantation setting |
| Q38110232 | Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. |
| Q51043349 | Clinical, biological, and immunophenotypical characteristics of B-cell chronic lymphocytic leukemia with trisomy 12 by fluorescence in situ hybridization. |
| Q68553840 | Combination of interferon and dexamethasone in refractory multiple myeloma |
| Q33587563 | Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial |
| Q47996009 | Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. |
| Q49246734 | Cytochemistry in the differential diagnosis of monoclonal gammopathies |
| Q71811565 | DNA aneuploidy in acute myeloblastic leukemia is associated with a high expression of lymphoid markers |
| Q34091328 | Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. |
| Q35924308 | Design and application of a 23-gene panel by next-generation sequencing for inherited coagulation bleeding disorders. |
| Q88211940 | Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction |
| Q36799831 | Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia. |
| Q51039328 | Differential stability of control gene and fusion gene transcripts over time may hamper accurate quantification of minimal residual disease--a study within the Europe Against Cancer Program. |
| Q60204043 | Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification |
| Q57595138 | Effect of mismatching for mHA UTA2-1 on clinical outcome after HLA-identical sibling donor allo-SCT |
| Q28255147 | Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia |
| Q51962180 | Expanded cells in monoclonal TCR-alphabeta+/CD4+/NKa+/CD8-/+dim T-LGL lymphocytosis recognize hCMV antigens. |
| Q68832690 | Expression of the FMC7 antigen in cases of B-lymphoproliferative diseases |
| Q38299428 | Extranodal and nodal diffuse large B cell lymphoma of the head and neck: two different entities? |
| Q44815840 | Frequency of HLA-A, -B and -DRB1 specificities and haplotypic associations in the population of Castilla y León (northwest-central Spain). |
| Q54572012 | Functional class switch recombination may occur 'in vivo' in Waldenström macroglobulinaemia. |
| Q92444518 | Genomic analysis of a familial myelodysplasia/acute myeloid leukemia and inherited RUNX1 mutations without a pre-existing platelet disorder |
| Q42537560 | Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption |
| Q45323385 | Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC). |
| Q72784379 | Helper/suppressor T-cell subpopulations in benign paraproteinaemia |
| Q47758619 | High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics. |
| Q27312570 | Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics |
| Q58051480 | Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling |
| Q89987625 | Identification of relapse-associated gene mutations by next-generation sequencing in low-risk acute myeloid leukaemia patients |
| Q73597491 | Immunoglobulin lambda isotype gene rearrangements in B cell malignancies |
| Q72928274 | Immunological features of sporadic multinodular goiter |
| Q33492521 | Immunophenotypic characterisation of acute leukaemia after polycythemia vera |
| Q60724766 | Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach |
| Q40025076 | Inhibition of proteasome by bortezomib causes intracellular aggregation of hepatic serpins and increases the latent circulating form of antithrombin. |
| Q37697093 | Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations |
| Q42071044 | Late differentiation syndrome in acute promyelocytic leukemia: a challenging diagnosis. |
| Q91821663 | Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population |
| Q35657063 | Long-term treatment results for acute megakaryoblastic leukaemia patients: a multicentre study |
| Q54541357 | Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor outcome in multiple myeloma. |
| Q68118175 | Lymphoid subsets and prognostic factors in multiple myeloma. Cooperative Group for the Study of Monoclonal Gammopathies |
| Q72105922 | Lymphoid subsets in acute myeloid leukemias: increased number of cells with NK phenotype and normal T-cell distribution |
| Q40783027 | MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion. |
| Q35496723 | MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. |
| Q35911998 | Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. |
| Q53267234 | Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia. |
| Q51839241 | Molecular and epidemiologic findings of childhood acute leukemia in Costa Rica. |
| Q83969782 | Molecular and flow cytometry characterization during the follow-up of three simultaneous lymphoproliferative disorders: hairy cell leukemia, monoclonal B-cell lymphocytosis, and CD4(++) /CD8(+/- dim) T-large granular lymphocytosis--a case report |
| Q80292625 | Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance |
| Q52947124 | Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. |
| Q60429932 | Monoclonal TCR-V 13.1+/CD4+/NKa+/CD8 /+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin |
| Q51327366 | Multiple cranial neuropathy and intracranial hypertension associated with all-trans retinoic acid treatment in a young adult patient with acute promyelocytic leukemia. |
| Q57082594 | Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome |
| Q53259951 | NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. |
| Q42050819 | Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. |
| Q39003105 | Origin of Waldenstrom's macroglobulinaemia |
| Q33424306 | Panobinostat as part of induction and maintenance for elderly patients with newly diagnosed acute myeloid leukemia: phase Ib/II panobidara study |
| Q46119032 | Pediatric primary follicular mucinosis: further evidence of its relationship with mycosis fungoides. |
| Q58041476 | Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification |
| Q69116246 | Plasmablastic multiple myeloma: an immunologically different subtype |
| Q48682753 | Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array. |
| Q57215177 | Primary cutaneous T-cell lymphoproliferative disorder of donor origin after allogeneic haematopoietic stem-cell transplantation |
| Q62078730 | Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia |
| Q72326951 | Prognostic implications of DNA aneuploidy in 156 untreated multiple myeloma patients. Castelano-Leonés (Spain) Cooperative Group for the Study of Monoclonal Gammopathies |
| Q39601375 | Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4+ and MLL-germline acute lymphoblastic leukemia. |
| Q33621587 | Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma |
| Q90898528 | Reply to Brown et al: 'Correct application of variant classification guidelines in germline RUNX1 mutated disorders to assist clinical diagnosis' |
| Q43689482 | Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients. |
| Q80258219 | Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies |
| Q87491377 | Role of minimal residual disease and chimerism after reduced-intensity and myeloablative allo-transplantation in acute myeloid leukemia and high-risk myelodysplastic syndrome |
| Q59602388 | SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status |
| Q35977542 | Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease. |
| Q58865842 | Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen |
| Q68480565 | Skin involvement in non-secretory myeloma |
| Q35561038 | Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. |
| Q60724701 | Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells |
| Q53533810 | Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. |
| Q84309154 | Sustained complete remission with single agent rituximab in relapsed follicular lymphoma as transformed disease after unrelated reduced intensity conditioning allogeneic stem cell transplantation |
| Q69971514 | T-cell subpopulations in patients with monoclonal gammopathies: essential monoclonal gammopathy, multiple myeloma, and Waldenstrom macroglobulinemia |
| Q68824058 | T-cell subsets and myeloma cell mass |
| Q42416286 | TET2 overexpression in chronic lymphocytic leukemia is unrelated to the presence of TET2 variations. |
| Q68733277 | TdT activity in acute myeloid leukemias defined by monoclonal antibodies |
| Q47244390 | The EuroChimerism concept for a standardized approach to chimerism analysis after allogeneic stem cell transplantation. |
| Q53011053 | The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy. |
| Q72031911 | The phenotype of L-CFU and its correlation with the immunological characteristics of the blast cell population in AML |
| Q53643731 | The predominant myeloma clone at diagnosis, CDR3 defined, is constantly detectable across all stages of disease evolution. |
| Q81041039 | The presence of DRB1*01 allele in multiple myeloma patients is associated with an indolent disease |
| Q54514626 | The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia. |
| Q54293484 | The use of CD138 positively selected marrow samples increases the applicability of minimal residual disease assessment by PCR in patients with multiple myeloma. |
| Q67899885 | The value of the immunological subtypes and individual markers compared to classical parameters in the prognosis of acute lymphoblastic leukemia |
| Q41363559 | UGT2B17 minor histocompatibility mismatch and clinical outcome after HLA-identical sibling donor stem cell transplantation. |
| Q79879693 | Using quantification of the PML-RARalpha transcript to stratify the risk of relapse in patients with acute promyelocytic leukemia |
| Q84336295 | [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia] |
| Q82535679 | [Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis] |
| Marcos González Díaz | wikipedia |
Search more.